Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

69 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Performance of serum marker panels for liver fibrosis in chronic hepatitis C.
Parkes J, Guha IN, Roderick P, Rosenberg W. Parkes J, et al. Among authors: guha in. J Hepatol. 2006 Mar;44(3):462-74. doi: 10.1016/j.jhep.2005.10.019. Epub 2005 Nov 21. J Hepatol. 2006. PMID: 16427156 Review.
METHODS: A systematic review was conducted to assess the performance of panels of serum markers of hepatic fibrosis in CHC, incorporating analyses placing markers in a clinical context. ...CONCLUSIONS: Serum markers can rule-in or rule-out fibrosis in
METHODS: A systematic review was conducted to assess the performance of panels of serum markers of hepatic fibrosis in CHC, incorpora …
Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.
Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Guha IN, et al. Gut. 2006 Nov;55(11):1650-60. doi: 10.1136/gut.2006.091454. Gut. 2006. PMID: 17047111 Free PMC article. Review.
We will discuss the biological plausibility, limitations, potential uses, and emerging diagnostic techniques of non-invasive markers in this rapidly expanding field....
We will discuss the biological plausibility, limitations, potential uses, and emerging diagnostic techniques of non-invasive markers in
Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic.
Muddu AK, Guha IN, Elsharkawy AM, Mann DA. Muddu AK, et al. Among authors: guha in. Int J Biochem Cell Biol. 2007;39(4):695-714. doi: 10.1016/j.biocel.2006.10.006. Epub 2006 Oct 7. Int J Biochem Cell Biol. 2007. PMID: 17110155 Review.
This review provides a critique of those discoveries in basic research that provide the most promise for translation to the clinic. In addition, we review the latest developments in the search for minimal invasive diagnostic tests for fibrosis that will be es …
This review provides a critique of those discoveries in basic research that provide the most promise for translation to the clinic. …
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.
Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Guha IN, et al. Hepatology. 2008 Feb;47(2):455-60. doi: 10.1002/hep.21984. Hepatology. 2008. PMID: 18038452
We validated the Original European Liver Fibrosis panel (OELF) and a simplified algorithm not containing age, the Enhanced Liver fibrosis panel (ELF), in an independent cohort of patients with NAFLD. ...One hundred ninety-six consecutively recruited patients from 2 centers …
We validated the Original European Liver Fibrosis panel (OELF) and a simplified algorithm not containing age, the Enhanced Liver fibrosis pa …
Back to the future with noninvasive biomarkers of liver fibrosis.
Guha IN. Guha IN. Hepatology. 2009 Jan;49(1):9-11. doi: 10.1002/hep.22735. Hepatology. 2009. PMID: 19111007 No abstract available.
Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus.
Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, Little AM, Alexander GJ, Rosenberg WM, Cramp ME, Khakoo SI. Knapp S, et al. Among authors: guha in. Hepatology. 2010 Apr;51(4):1168-75. doi: 10.1002/hep.23477. Hepatology. 2010. PMID: 20077564 Free PMC article.
Homozygosity for KIR2DL3 in combination with group 1 HLA-C allotypes was more frequent in exposed seronegative aviremic individuals as compared to those with chronic HCV (25.0% versus 9.7%, P = 0.003, odds ratio [OR] = 3.1, 95% confidence interval [CI] = 1.3-7.1) …
Homozygosity for KIR2DL3 in combination with group 1 HLA-C allotypes was more frequent in exposed seronegative aviremic indivi …
Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?
Guha IN, Myers RP, Patel K, Talwalkar JA. Guha IN, et al. Hepatology. 2011 Oct;54(4):1454-62. doi: 10.1002/hep.24515. Epub 2011 Aug 9. Hepatology. 2011. PMID: 21725995 Review.
Despite the rapid progress in recent years, there remain questions about how diagnostic studies are designed, statistical methods to account for spectrum bias, clinically relevant thresholds of fibrosis that should be delineated, how diagnostics can be improved, and streng …
Despite the rapid progress in recent years, there remain questions about how diagnostic studies are designed, statistical methods to …
Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans.
Pritchett J, Harvey E, Athwal V, Berry A, Rowe C, Oakley F, Moles A, Mann DA, Bobola N, Sharrocks AD, Thomson BJ, Zaitoun AM, Irving WL, Guha IN, Hanley NA, Hanley KP. Pritchett J, et al. Among authors: guha in. Hepatology. 2012 Sep;56(3):1108-16. doi: 10.1002/hep.25758. Hepatology. 2012. PMID: 22488688 Free PMC article.
During normal development and in the mature liver, SOX9 and OPN are coexpressed in the biliary duct. In rodent and human models of fibrosis, both proteins were increased and colocalized to fibrotic regions in vivo and in culture-activated HSCs. …
During normal development and in the mature liver, SOX9 and OPN are coexpressed in the biliary duct. In rodent and huma …
Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Tanwar S, et al. Among authors: guha in. Hepatology. 2013 Jan;57(1):103-11. doi: 10.1002/hep.26030. Hepatology. 2013. PMID: 22930399 Clinical Trial.
The aim of this study was to identify a biomarker of NASH in patients without significant fibrosis. In all, 172 patients from two centers with biopsy-proven NAFLD were included in this study. ...Area under receiver operating characteristic curve (AUROC) for P …
The aim of this study was to identify a biomarker of NASH in patients without significant fibrosis. In all, 172 patients from …
Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease.
Parkes J, Guha IN, Harris S, Rosenberg WM, Roderick PJ. Parkes J, et al. Among authors: guha in. Comp Hepatol. 2012 Dec 28;11(1):5. doi: 10.1186/1476-5926-11-5. Comp Hepatol. 2012. PMID: 23273224 Free PMC article.
CONCLUSIONS: There are limited numbers of small studies evaluating the accuracy of biomarkers in identifying fibrosis on biopsy in ALD. Some showed promise (both HA alone and some panels) in the identification of cirrhosis/severe fibrosis and could be used to …
CONCLUSIONS: There are limited numbers of small studies evaluating the accuracy of biomarkers in identifying fibrosis on biopsy in
69 results
Jump to page
Feedback